目的：观察厄贝沙坦联合硝苯地平缓释片对糖尿病合并高血压病的降压效果及对肾脏的保护作用。方法：糖尿病合并高血压病患者90例随机分为厄贝沙坦组、硝苯地平缓释片组及联合治疗组三组，每组各30例，均治疗12周，三组分别测定治疗前后静息状态下血压及24小时尿微量白蛋白。结果：治疗12周后各组收缩压、舒张压均较治疗前明显下降，差异有统计学意义( P <0.05)；而联合治疗组降压疗效优于厄贝沙坦组和硝苯地平缓释片组，差异有统计学意义(P <0.05)。治疗后联合治疗组和厄贝沙坦组24小时尿微量白蛋白均较治疗前明显下降，差异有统计学意义( P <0.05)。结论：厄贝沙坦联合硝苯地平缓释片治疗糖尿病合并高血压病效果优于单一用药，能使血压达到理想控制标准值，减轻靶器官损害，且无明显不良反应。
To access the efficacy and the protection to kidney function of using irbesartan combining with extended release nifedipine tablet in the treatment of hypertension in patients with type2 diabetes mel itus. Methods: Patients diagnosed with hypertension and type2 diabetes mel itus (N=90) were randomly separated into three groups, in which 30 patients were assigned in each group. The patients were treated with irbesartan, or extended release nifedipine tablte, or both, respectively. After 12 weeks of treatment, patients from each groups were evaluated by their resting blood pressure and 24-hour urine protein. Result: After 12 weeks of treatment, the systolic pressure, as wel as diastolic pressure, of patients from al groups are significantly reduced (P<0.05). The group treated with both irbesartan and extended release nifedipine tablet showed a better efficacy compared to other two groups that use either irbesartan or nifedipine only (P<0.05). The 24-hour urine protein was significantly reduced in the group treated with irbesartan and the group treated with irbesartan and nifedipin (P<0.05). Conclusion: Treatment of irbesartan combining with extended release nefidipine showed better control of hypertension in patient with type2 diabetes, compared to treatment with either of them only. The combining treatment can reduce blood pressure to ideal range, minimize kidney damage and show very limited side effect.
NETL
NSTL
万方数据
